ENXTPA:ABVXBiotechs
Abivax ECCO Data Sharpen Obefazimod’s IBD Opportunity And Investor Focus
Abivax (ENXTPA:ABVX) presented new preclinical and clinical data for obefazimod at the ECCO Congress.
The data highlighted anti fibrotic activity in Crohn's disease and rapid symptomatic relief in inflammatory bowel disease.
Large Phase 3 trials were reported to show a strong safety profile and further validation of obefazimod's miR 124 targeting mechanism.
Abivax focuses on inflammatory and autoimmune diseases, with obefazimod positioned as its lead asset in inflammatory bowel disease. For...